BBOT Q4 2025 Earnings — BridgeBio Oncology Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BBOTBridgeBio Oncology Therapeutics Inc.

$820M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$194,000

Operating Income

-$64M

Net Income

-$39M

EPS (Diluted)

$-0.48

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$375,546

Free Cash Flow

-$55,546

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$448M

Total Liabilities

$37M

Stockholders' Equity

$411M

Cash & Equivalents

$374M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$194,000	$0	—
Operating Income	-$64M	-$22M	-193.1%
Net Income	-$39M	-$20M	-97.1%